Advances in Gynecological Oncology: From Pathogenesis to Therapy (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 18 December 2024 | Viewed by 87
Special Issue Editor
Interests: cervical intraepithelial neoplasia; HPV-related diseases; gynecological oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This collection is the second edition of the Special Issue “Advances in Gynecological Oncology: From Pathogenesis to Therapy ” (https://www.mdpi.com/journal/cancers/special_issues/Advances_Gynecological_Oncology_Pathogenesis_Therapy).
The histological categories of some gynecological tumors do not accurately differentiate the clinical course and response to therapy. Currently, a molecular profile study is being carried out to improve the risk stratification and targeted therapy for endometrial cancer. Biomarkers and molecular alterations are increasingly being used to choose the best systemic treatment. It is also now evident that molecular characteristics affect the biological behavior and chemo-sensitivity of ovarian carcinomas. Advanced cervical cancer and recurrences respond poorly to chemotherapy. The HPV vaccine plays a crucial role in preventing this disease, and its coverage should be implemented worldwide.
There is a further need to identify better biomarkers that allow for personalized therapy and combined therapeutic regimens, including immunotherapy, radiation therapy and chemotherapy, and personalized fertility-sparing treatment in young women should be considered when feasible.
In several gynecological cancers, sentinel lymph node use showed decreased morbidity, high sensitivity and a high negative predictive value. Many surgeons reserve its use for intermediate/high-risk patients, but further evidence is needed in this area.
This Special Issue aims to gather reviews and original contributions in one collection to illustrate recent advances in gynecological cancers and the future directions of clinical and basic research.
Dr. Andrea Ciavattini
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer
- uterine cancer
- cervical cancer
- vulvar cancer
- biomarkers
- HPV vaccine
- sentinel lymph node evaluation
- fertility-sparing treatment
- recurrent gynecological cancer
- molecular profile
- immunotherapy
- chemotherapy
- radiotherapy
- hormonal therapy
- imaging
